PURPOSE: Neoadjuvant intense androgen deprivation therapy (iADT) can exert a wide range of histological responses, which in turn are reflected in the final prostatectomy specimen. Accurate identification and measurement of residual tumor volumes are critical for tracking and stratifying patient outcomes. MATERIALS AND METHODS: The goal of this current study was to evaluate the ability of antibodies against prostate-specific membrane antigen (PSMA) to specifically detect residual tumor in a cohort of 35 patients treated with iADT plus enzalutamide for 6 months prior to radical prostatectomy. RESULTS: Residual carcinoma was detected in 31 patients, and PSMA reacted positively with tumor in all cases. PSMA staining was 96% sensitive for tumor, with approximately 82% of benign regions showing no reactivity. By contrast, PSMA positively reacted with 72% of benign regions in a control cohort of 37 untreated cases, resulting in 28% specificity for tumor. PSMA further identified highly dedifferentiated prostate carcinomas including tumors with evidence of neuroendocrine differentiation. CONCLUSIONS: We propose that anti-PSMA immunostaining be a standardized marker for identifying residual cancer in the setting of iADT.
PURPOSE: Neoadjuvant intense androgen deprivation therapy (iADT) can exert a wide range of histological responses, which in turn are reflected in the final prostatectomy specimen. Accurate identification and measurement of residual tumor volumes are critical for tracking and stratifying patient outcomes. MATERIALS AND METHODS: The goal of this current study was to evaluate the ability of antibodies against prostate-specific membrane antigen (PSMA) to specifically detect residual tumor in a cohort of 35 patients treated with iADT plus enzalutamide for 6 months prior to radical prostatectomy. RESULTS: Residual carcinoma was detected in 31 patients, and PSMA reacted positively with tumor in all cases. PSMA staining was 96% sensitive for tumor, with approximately 82% of benign regions showing no reactivity. By contrast, PSMA positively reacted with 72% of benign regions in a control cohort of 37 untreated cases, resulting in 28% specificity for tumor. PSMA further identified highly dedifferentiated prostate carcinomas including tumors with evidence of neuroendocrine differentiation. CONCLUSIONS: We propose that anti-PSMA immunostaining be a standardized marker for identifying residual cancer in the setting of iADT.
Authors: Matthias Eiber; Ken Herrmann; Jeremie Calais; Boris Hadaschik; Frederik L Giesel; Markus Hartenbach; Thomas Hope; Robert Reiter; Tobias Maurer; Wolfgang A Weber; Wolfgang P Fendler Journal: J Nucl Med Date: 2017-11-09 Impact factor: 10.057
Authors: Sofia Vaz; Boris Hadaschik; Michael Gabriel; Ken Herrmann; Matthias Eiber; Durval Costa Journal: Eur J Nucl Med Mol Imaging Date: 2020-01 Impact factor: 9.236
Authors: Neil A Abrahams; David G Bostwick; Adrian H Ormsby; Junqi Qian; Jennifer A Brainard Journal: Am J Clin Pathol Date: 2003-09 Impact factor: 2.493
Authors: Julie L Kasperzyk; Stephen P Finn; Richard Flavin; Michelangelo Fiorentino; Rosina Lis; Whitney K Hendrickson; Steven K Clinton; Howard D Sesso; Edward L Giovannucci; Meir J Stampfer; Massimo Loda; Lorelei A Mucci Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-10-15 Impact factor: 4.254
Authors: Gaëtan Devos; Wout Devlies; Gert De Meerleer; Marcella Baldewijns; Thomas Gevaert; Lisa Moris; Daimantas Milonas; Hendrik Van Poppel; Charlien Berghen; Wouter Everaerts; Frank Claessens; Steven Joniau Journal: Nat Rev Urol Date: 2021-09-15 Impact factor: 14.432
Authors: Leonard M da Silva; Emilio M Pereira; Paulo Go Salles; Ran Godrich; Rodrigo Ceballos; Jeremy D Kunz; Adam Casson; Julian Viret; Sarat Chandarlapaty; Carlos Gil Ferreira; Bruno Ferrari; Brandon Rothrock; Patricia Raciti; Victor Reuter; Belma Dogdas; George DeMuth; Jillian Sue; Christopher Kanan; Leo Grady; Thomas J Fuchs; Jorge S Reis-Filho Journal: J Pathol Date: 2021-04-27 Impact factor: 7.996
Authors: Christopher C Parker; Nicholas D James; Christopher D Brawley; Noel W Clarke; Alex P Hoyle; Adnan Ali; Alastair W S Ritchie; Gerhardt Attard; Simon Chowdhury; William Cross; David P Dearnaley; Silke Gillessen; Clare Gilson; Robert J Jones; Ruth E Langley; Zafar I Malik; Malcolm D Mason; David Matheson; Robin Millman; J Martin Russell; George N Thalmann; Claire L Amos; Roberto Alonzi; Amit Bahl; Alison Birtle; Omar Din; Hassan Douis; Chinnamani Eswar; Joanna Gale; Melissa R Gannon; Sai Jonnada; Sara Khaksar; Jason F Lester; Joe M O'Sullivan; Omi A Parikh; Ian D Pedley; Delia M Pudney; Denise J Sheehan; Narayanan Nair Srihari; Anna T H Tran; Mahesh K B Parmar; Matthew R Sydes Journal: Lancet Date: 2018-10-21 Impact factor: 79.321
Authors: Marco Bergamini; Alberto Dalla Volta; Irene Caramella; Luisa Bercich; Simona Fisogni; Mattia Bertoli; Francesca Valcamonico; Salvatore Grisanti; Pietro Luigi Poliani; Francesco Bertagna; Alfredo Berruti Journal: Front Oncol Date: 2022-07-22 Impact factor: 5.738